Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor...
20 insider purchases on record · latest filing 2026-07-06.
Insiders have also filed 4 sale transactions at ABSI.